196 related articles for article (PubMed ID: 31363010)
1. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
2. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models.
Wang J; Chen T; Ruszaj DM; Mager DE; Straubinger RM
J Pharm Sci; 2024 Jan; 113(1):72-84. PubMed ID: 37844759
[TBL] [Abstract][Full Text] [Related]
3. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.
Roy Chaudhuri T; Straubinger NL; Pitoniak RF; Hylander BL; Repasky EA; Ma WW; Straubinger RM
Mol Cancer Ther; 2016 Jan; 15(1):84-93. PubMed ID: 26516158
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.
Kim YJ; Jung K; Baek DS; Hong SS; Kim YS
Oncogene; 2017 May; 36(18):2543-2552. PubMed ID: 27797376
[TBL] [Abstract][Full Text] [Related]
7. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model.
Guimaraes AR; Rakhlin E; Weissleder R; Thayer SP
Pancreas; 2008 Nov; 37(4):440-4. PubMed ID: 18953259
[TBL] [Abstract][Full Text] [Related]
9. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer.
Lodestijn SC; Miedema DM; Lenos KJ; Nijman LE; Belt SC; El Makrini K; Lecca MC; Waasdorp C; van den Bosch T; Bijlsma MF; Vermeulen L
Cell Rep; 2021 Oct; 37(3):109852. PubMed ID: 34686335
[TBL] [Abstract][Full Text] [Related]
10. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.
Damhofer H; Medema JP; Veenstra VL; Badea L; Popescu I; Roelink H; Bijlsma MF
Mol Oncol; 2013 Dec; 7(6):1031-42. PubMed ID: 23998958
[TBL] [Abstract][Full Text] [Related]
13. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
15. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer.
Onishi H; Kai M; Odate S; Iwasaki H; Morifuji Y; Ogino T; Morisaki T; Nakashima Y; Katano M
Cancer Sci; 2011 Jun; 102(6):1144-50. PubMed ID: 21338440
[TBL] [Abstract][Full Text] [Related]
17. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.
Rhim AD; Oberstein PE; Thomas DH; Mirek ET; Palermo CF; Sastra SA; Dekleva EN; Saunders T; Becerra CP; Tattersall IW; Westphalen CB; Kitajewski J; Fernandez-Barrena MG; Fernandez-Zapico ME; Iacobuzio-Donahue C; Olive KP; Stanger BZ
Cancer Cell; 2014 Jun; 25(6):735-47. PubMed ID: 24856585
[TBL] [Abstract][Full Text] [Related]
18. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]